key: cord-1003634-3vul0bjk
authors: Etminan, Mahyar; Sodhi, Mohit; Ganjizadeh-Zavareh, Saeed
title: Should Antipyretics be used to Relieve Acute Adverse Events Related to COVID-19 Vaccines?
date: 2021-02-05
journal: Chest
DOI: 10.1016/j.chest.2021.01.080
sha: 61e3efcb85473b14d410da44a626708a0ba20279
doc_id: 1003634
cord_uid: 3vul0bjk

nan

The introduction of new vaccines against COVID-19 including those from BioNTech and Moderna, among others, will be pivotal for controlling the SARS-CoV-2 pandemic. The availability and administration of these vaccines will be a pivotal step in controlling the COVID-19 pandemic.

The BioNTech and Moderna vaccines are currently the only ones approved for use in North America. These two vaccines, like many others, might also be associated with self-limiting acute adverse reactions (ADRs). The overall rate of systemic ADRs, based on recently published phase three trial data 1,2 is considered low. For example, in the trial that used the BioNTech vaccine (18,860 vaccine users vs. 18,846 nonusers) the overall ADR rates with the first dose was 0.9% 1 . However, a considerable proportion of vaccine recipients still reported fatigue (59% vs 52%, vaccine vs placebo users) and headache (51% vs. 39% among older recipients). Similarly, more patients taking the Moderna vaccine reported any systemic reaction (79.6% vs. 36.6.0%).

Specifically, more subjects experienced myalgia (58.0% vs. 12.3%), arthralgia (42.9 % vs. 10.7%) and fatigue (65.7% vs. 23.3) with the vaccine 2 . Based on these data and given the availability of antipyretics as over the counter medications, it is expected that potentially millions around the world might be using them to control acute systemic ADRs related to the COVID-19 vaccine.

Historically, antipyretics such as ibuprofen or acetaminophen have been used to control the acute phase adverse events secondary to different vaccines. However, some studies have suggested that taking antipyretics immediately before or shortly after receiving a vaccine might interfere with its immunogenicity 3 , while some have not 4 . A two-part landmark randomised trial evaluated the effect of acetaminophen taken prophylactically (immediately following vaccination) in infants 3 . In this study, antibody titers were significantly lowered in those taking acetaminophen prophylactically compared to controls. Moreover, some of the differences in these findings might be due to age as the potential immune modulating effects of antipyretics and their potential negative interaction with vaccines might differ in children and adults. 

The mechanism of decreased circulating antibodies due to antipyretic administration post-vaccination is not well understood; however, a few potential mechanisms have been postulated. Antipyretics such as acetaminophen and ibuprofen can interfere with the communication between the innate and adaptive immune system in lymphatic tissue, which occurs within hours of antigen administration. Most of the research on this topic has been undertaken looking at the effect of antibody production with antipyretics using animal models which warrants more human data from vaccines that use different platforms (protein, live attenuated or mRNA-based vaccines).

To date, no study has specifically examined the effect antipyretics on the immunogenicity of the COVID-19 vaccines. A recent report from the ½ single-blind randomised trial of the AstraZeneca (adenovirus-vectored vaccine) does mention that prophylactic use of acetaminophen did not interfere with the vaccine's immunogenicity although no data were provided, and these results might not be applicable to other mRNA type vaccines. Furthermore, there was no data provided on the use of antipyretics in the Moderna 2 trial, while the Pfizer 1 trial only mentioned that the use of antipyretics was increased with increasing dose concentrations and dose number, but data on immunogenicity were not given.

A potential negative interaction between antipyretic use and COVID-19 vaccines might have important public health repercussions, as they potentially affect the efficacy of the vaccine directly by hindering the vaccine's immune response. Indirectly, concerns about this interaction can lead to low utilization of antipyretics and potentially lead to non-adherence to the second

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine -2 -Preliminary Report

Effect of prophylactic acetaminophen administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials

Effects of prophylactic and therapeutic acetaminophen treatment during vaccination on hepatitis B antibody levels in adults: two openlabel, randomized controlled trials

CDC General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP)